Delivery Order SPE2DB22D1106-SPE2DB25FFHT6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,439.09 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Barhemsys 10 mg/4 ml vials. This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 26, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $4,523.99 to AmerisourceBergen Drug Corp for BARHEMSYS 10 mg/4 ml vials on September 8, 2025, with completion targeted for September 9, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, was selected to...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of the drug BARHEMSYS 5 MG/2 ML VIAL 2ML. The contract has a firm fixed price of $1,621.32 and a completion date of July 25, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the provision of...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is for the delivery of 4567212297 - BARHEMSYS 5 MG/2 ML VIAL 2ML, a pharmaceutical product. The contract is a Delivery Order with a Firm Fixed Price of $1,310.68 and has a completion date of February 11, 2025. This award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,159.02, is for the supply of BARHEMSYS 5 MG/2 ML VIAL 2ML, a pharmaceutical product. This is a delivery order contract with a firm fixed price pricing type and an ultimate completion date of January 9, 2024. The contract does not have a set-aside designation, indicating open competition....
- This federal contract award, valued at $1,462.45, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BARHEMSYS 5 MG/2 ML VIAL 2ML, a pharmaceutical product, with a completion date of December 13, 2024. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $1,664.83 to AmerisourceBergen Drug Corp on September 10, 2025, with an ultimate completion date of September 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The work will be performed at the contractor's corporate office in Conshohocken, Pennsylvania....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $3,708.00 to AmerisourceBergen Drug Corp on September 10, 2025, with an ultimate completion date of September 11, 2025. This firm fixed-price delivery order, issued under contract number 4569424241, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a firm fixed-price delivery order valued at $17,524.44 to AmerisourceBergen Drug Corp on July 27, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $2,724.96 to AmerisourceBergen Drug Corp on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery vehicle with DLA and carries no set-aside designation. The order will be fulfilled from the vendor's corporate office location in Conshohocken,...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFHT6Delivery Order
The Defense Logistics Agency (DLA) awarded a $21,443.69 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Barhemsys 10 mg/4 mL vials. The contract, which is classified as a child delivery order under a larger indefinite delivery vehicle, carries an ultimate completion date of September 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for military and veteran healthcare systems, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support the Defense Health Agency and other federal healthcare customers. The firm fixed pricing structure and the contractor's extensive portfolio of federal medical product deliveries underscore its role as a primary vehicle for fulfilling DLA's pharmaceutical supply chain needs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.4k | 9/9/25 |